SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.
PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.
Researchers performed a retrospective cohort study by identifying patients from the Optum Clinformatics database who were initiated on canagliflozin 300mg or dapagliflozin 100mg from January 1, 2014 to September 30, 2016.
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.